Synonym
SCH-50911; SCH 50911; SCH50911.
IUPAC/Chemical Name
(S)-2-(5,5-dimethylmorpholin-2-yl)acetic acid
SMILES Code
CC1(CO[C@H](CN1)CC(O)=O)C
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
More Info
SCH-50911 is likely to be a useful antidote for GHB overdose in non-addicted individuals, its use in people who are dependent on GHB or its analogues could be potentially dangerous as it might precipitate acute withdrawal symptoms, and additional anticonvulsants such as diazepam would most likely be required to counteract the risk of life-threatening seizures.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
173.21
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: van Nieuwenhuijzen PS, McGregor IS, Chebib M, Hunt GE. Regional Fos-expression induced by γ-hydroxybutyrate (GHB): comparison with γ-butyrolactone (GBL) and effects of co-administration of the GABAB antagonist SCH 50911 and putative GHB antagonist NCS-382. Neuroscience. 2014 Sep 26;277:700-15. doi: 10.1016/j.neuroscience.2014.07.056. Epub 2014 Aug 1. PubMed PMID: 25088910.
2: Carai MA, Colombo G, Gessa GL. Protection by the GABAB receptor antagonist, SCH 50911, of gamma-hydroxybutyric acid-induced mortality in mice. Eur J Pharmacol. 2004 Oct 25;503(1-3):77-80. PubMed PMID: 15496299.
3: Carai MA, Brunetti G, Lobina C, Serra S, Vacca G, Minardi G, Colombo G, Gessa GL. Proconvulsive effect of the GABA(B) receptor antagonist, SCH 50911, in rats undergoing ethanol withdrawal syndrome. Eur J Pharmacol. 2002 Jun 12;445(3):195-9. PubMed PMID: 12079684.
4: Erhardt S, Nissbrandt H, Engberg G. Activation of nigral dopamine neurons by the selective GABA(B)-receptor antagonist SCH 50911. J Neural Transm. 1999;106(5-6):383-94. PubMed PMID: 10443545.
5: Ong J, Marino V, Parker DA, Kerr DI, Blythin DJ. The morpholino-acetic acid analogue Sch 50911 is a selective GABA(B) receptor antagonist in rat neocortical slices. Eur J Pharmacol. 1998 Nov 27;362(1):35-41. PubMed PMID: 9865527.
6: Hosford DA, Wang Y, Liu CC, Snead OC 3rd. Characterization of the antiabsence effects of SCH 50911, a GABA-B receptor antagonist, in the lethargic mouse, gamma-hydroxybutyrate, and pentylenetetrazole models. J Pharmacol Exp Ther. 1995 Sep;274(3):1399-403. PubMed PMID: 7562514.
7: Bolser DC, Blythin DJ, Chapman RW, Egan RW, Hey JA, Rizzo C, Kuo SC, Kreutner W. The pharmacology of SCH 50911: a novel, orally-active GABA-beta receptor antagonist. J Pharmacol Exp Ther. 1995 Sep;274(3):1393-8. PubMed PMID: 7562513.